We demonstrated, both in vitro and in vivo, that FABP4 and FABP5, and their associated CYP2C19/EET signaling axis provide a regulatory mechanism in TNBC metastatic progression, regardless of whether they are intrinsically expressed by cancer cells or are activated through interaction with other cell types. Here, FABP4 is linked to cancer.